CMS Blood Brain Barrier Osmotic Disruption for Treatment of Brain Tumors Form
Procedure is not covered
Background for this Policy
A. General
The blood brain barrier (BBB) of the central nervous system is characterized by tight junctions between vascular endothelial cells, which prevent or impede various naturally occurring and synthetic substances (including anti-cancer drugs) from entering brain tissue. The BBB may be partly responsible for the poor efficacy of chemotherapy for malignant primary or metastatic brain tumors.
The BBBD is the disruption of the tight junctions between the endothelial cells that line the capillaries in the brain accomplished by osmotic disruption, bradykinin or irradiation. Theoretically, disruption of the BBB may, in the treatment of brain tumors, increase the concentration of chemotherapy drugs delivered to the tumor and may prolong the drug-tumor contact time.
Osmotic disruption of the BBB is the most common technique used. Chemotherapeutic agents are given in conjunction with barrier disruption. The BBBD process includes all items and services necessary to perform the procedure, including hospitalization, monitoring, and repeated imaging procedures.
B. Nationally Covered Indications
N/A
C. Nationally Non-Covered Indications
Effective for services performed on and after March 20, 2007, the Centers for Medicare & Medicaid Services determines that the use of osmotic BBBD is not reasonable and necessary when it is used as part of a treatment regimen for brain tumors.
D. Other
This NCD does not alter in any manner the coverage of anti-cancer chemotherapy.
(This NCD last reviewed March 2007.)